Gastric Cancer (PD-L1 Expression): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 55-year-old male with 2 months’ history of shortness of breath, lethargy, and anemia with a 6kg weight loss. His hypertension is well controlled on losartan. He has no other co-morbidities and no relevant family history. He is a non-smoker and his alcohol intake is 6 drinks per week. He had a 19-year-old daughter who died from acute lymphocytic leukemia 4 years ago. An upper gastrointestinal endoscopy showed a 6 cm ulcer in the gastric fungus and biopsy showed poorly differentiated intestinal type adenocarcinoma, HER2 negative. CT scans revealed a T4N1M2 gastric adenocarcinoma with coeliac axis and retroperitoneal lymphadenopathy.

Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives

  • Evaluate the data for immune checkpoint inhibitors for patients with advanced gastric cancer
  • Analyze the predictive factors that have been researched regarding response to immune checkpoint inhibitors
  • Discuss available PD-1/PD-L1 inhibitors and their safety profiles including the most common immune-related adverse events

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on December 21, 2019. Participants must complete all necessary course components by this date to receive credit.